As of 14 Oct 2026, Biolinq has raised $100M across 1 verified round on record; latest: $100 million Series C led by Alpha Wave, announced 22 Apr 2025.
Biolinq sells wearable biosensor technology that monitors glucose levels for health and metabolic insights.
1 source
The company release identifies the eight participants as existing investors; they are included because it explicitly says they participated in this financing.
Published by hand (biolinq.com): "Biolinq today announced a $100 million Series C financing led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital.": biggest-rounds completeness (K): the row's own page states the round
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-04-22 | Alpha Wave | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
The company release identifies the eight participants as existing investors; they are included because it explicitly says they participated in this financing. Published by hand (biolinq.com): "Biolinq today announced a $100 million Series C financing led by Alpha Wave Ventures, with participation from existing investors RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital.": biggest-rounds completeness (K): the row's own page states the round | ||||